Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 121.56%.

  • Enanta Pharmaceuticals' EBIT Margin rose 828200.0% to 121.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 130.65%, marking a year-over-year increase of 492700.0%. This contributed to the annual value of 130.65% for FY2025, which is 492700.0% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' EBIT Margin is 121.56%, which was up 828200.0% from 103.16% recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' EBIT Margin ranged from a high of 103.16% in Q2 2025 and a low of 221.7% during Q1 2023
  • Moreover, its 5-year median value for EBIT Margin was 156.53% (2021), whereas its average is 157.79%.
  • In the last 5 years, Enanta Pharmaceuticals' EBIT Margin crashed by -1045300bps in 2021 and then skyrocketed by 828200bps in 2025.
  • Enanta Pharmaceuticals' EBIT Margin (Quarter) stood at 109.99% in 2021, then dropped by -16bps to 127.25% in 2022, then crashed by -52bps to 193.78% in 2023, then increased by 28bps to 138.82% in 2024, then increased by 12bps to 121.56% in 2025.
  • Its EBIT Margin was 121.56% in Q3 2025, compared to 103.16% in Q2 2025 and 164.32% in Q1 2025.